Physician

Alaa Muslimani, MD

According to 2025 Medicare claims, Alaa Muslimani, MD (NPI: 1881887826) practices medical oncology in the Charlotte-Concord-Gastonia, NC-SC market, with the plurality of this provider's patient population coming from York, SC. This provider's primary affiliated billing organization is THE CHARLOTTE-MECKLENBURG HOSPITAL AUTHORITY (NPI: 1306269691; TIN: 56-0529945) and primary practice location at 29732-1724. Muslimani is affiliated with the Carolinas HealthCare System ACO, LLC (ACO ID: A3675), participating under the MSSP model.

Muslimani's data goes back to 2015 and runs through 2024. For example, in 2024, this provider had 730 traditional Medicare patients, billed 220,056 HCPCS/CPT codes, and received $4,611,935 in Medicare payments. The top billing code was 96413 (Administration of chemotherapy into vein, 1 hour or less). Part D data shows 2,562 prescription claims across 414 beneficiaries totaling $5,213,863 in drug costs, led by Imbruvica (Ibrutinib). DME data shows 99 claims. No Open Payments records. You can download detailed data with all billing codes (2015-2024). For more recent data, please contact us.

Over the past 10 years, this provider's Medicare Part B carrier billing has moved sharply higher in recent years, from $81,582 to $4,611,935. Similarly, Part D prescription costs have risen steadily, from $637,744 to $5,213,863. For DME billing, this provider has fewer than 5 years of reported data, so a reliable trend cannot be assigned.

Part B Carrier Billing Trend

Medicare payment trend, with N of patients and claim lines in the table.

Year	Patients	Clm Lines	Payment
2015	393	2,579	$81,582
2016	244	50,124	$404,060
2017	344	98,721	$1,162,253
2018	387	133,948	$1,453,556
2019	460	165,542	$2,154,936
2020	560	194,474	$2,704,950
2021	705	198,878	$2,876,748
2022	656	213,973	$3,894,260
2023	728	244,007	$3,956,488
2024	730	220,056	$4,611,935

Part D Events Trend

Drug cost trend, with N of patients and prescription claims in the table.

Year	Patients	Claims	Drug Cost
2015	98	556	$637,744
2016	114	560	$522,776
2017	126	689	$915,076
2018	155	962	$1,298,853
2019	187	1,212	$2,391,588
2020	241	1,558	$3,258,686
2021	304	1,858	$3,254,016
2022	381	2,108	$2,807,006
2023	418	2,456	$3,579,396
2024	414	2,562	$5,213,863

DME Billing Trend

Medicare payment trend, with N of patients and DME claim records in the table.

Year	Patients	Claims	Payment
2015	N/R	28	$12,044
2016	N/R	N/R	N/R
2017	N/R	60	$7,616
2018	N/R	66	$2,127
2019	N/R	24	$2,860
2020	N/R	83	$6,535
2021	N/R	104	$7,382
2022	24	115	$3,878
2023	32	195	$33,128
2024	N/R	99	$2,399

* / # = suppressed by CMS; 0 = reported zero; N/R = not reported or blank.

Top 5 Part B carrier billing codes in 2024

By total payments.

Code	Description	Patients	Clm Lines	Total Payment
96413	Administration of chemotherapy into vein, 1 hour or less	134	515	$89
99214	Established patient office or other outpatient visit with moderate level of decision making, if using time, 30 minutes or more	477	1,378	$86
99213	Established patient office or other outpatient visit with low level od decision making, if using time, 20 minutes or more	171	229	$58
80053	Blood test, comprehensive group of blood chemicals	575	2,198	$10
85025	Complete blood cell count (red cells, white blood cell, platelets), automated test and automated differential white blood cell count	607	2,270	$8

Top 5 Part D drugs in 2024

By total drug costs.

Drug	Generic	Claims	Total Day Supply	Total Drug Cost
Imbruvica	Ibrutinib	38	1,064	$598,334
Jakafi	Ruxolitinib Phosphate	36	1,065	$515,846
Lenalidomide	Lenalidomide	34	952	$476,141
Calquence	Acalabrutinib Maleate	26	780	$387,629
Revlimid	Lenalidomide	17	476	$348,601

Top 5 DME services in 2024

By Total Medicare Payment Amount.

HCPCS Code	HCPCS Description	Supplier Rental Indicator	Total Supplier Beneficiaries	Total Supplier Claims	Total Medicare Payment Amount
J8521	Capecitabine, oral, 500 mg	N	N/R	42	$1,477
Q0511	Pharmacy supply fee for oral anti-cancer, oral anti-emetic or immunosuppressive drug(s); for the first prescription in a 30-day period	N	N/R	38	$696
Q0512	Pharmacy supply fee for oral anti-cancer, oral anti-emetic or immunosuppressive drug(s); for a subsequent prescription in a 30-day period	N	N/R	19	$226

Open Payments Summary

No connected Open Payments records were found for this physician in General Payments, Research Payments, or Ownership / Investment Interests.

Explore More Providers

FAQ

What Medicare data is available for Alaa Muslimani, MD?

Tedicare shows public-source Medicare data for Alaa Muslimani, MD (NPI 1881887826), including provider identity, specialty, market context, Medicare Part B activity, Part D prescribing, DME records, Open Payments where available, billing organization details, and ACO affiliation signals where available. Profile data covers 2015-2024, with current attribution based on 2025 claims where available.

Does Alaa Muslimani, MD have ACO affiliation data?

Alaa Muslimani, MD is shown with ACO affiliation data for Carolinas HealthCare System ACO, LLC (MSSP, ACO ID A3675).

What billing organization is linked to Alaa Muslimani, MD?

Alaa Muslimani, MD is linked to THE CHARLOTTE-MECKLENBURG HOSPITAL AUTHORITY (billing NPI 1306269691) in the available physician profile data.

Does Alaa Muslimani, MD have Open Payments data?

No connected Open Payments records are shown for this physician in the available General Payments, Research Payments, or Ownership / Investment Interests data.

Can I download physician-level Medicare data from Tedicare?

Yes. Tedicare provides sample physician export data and paid custom physician data exports for research, planning, outreach, and market analysis. Exports can include physician profile fields, market and specialty context, billing organization details, ACO affiliation signals where available, and Medicare utilization data.